Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.37 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.35 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448156 | 1.00 | IDH1 (0.37) | IDH1SYKMAPK3EGFRBTK | |
| SCHEMBL3448626 | 0.94 | MAPK3 (0.40) | SYKMAPK3EGFRBTKKDR | |
| SCHEMBL3448610 | 0.94 | MAPK3 (0.40) | SYKMAPK3EGFRBTKKDR | |
| SCHEMBL13312476 | 0.90 | THRB (0.37) | IDH1SYKMAPK3EGFRBTK | |
| SCHEMBL3451797 | 0.90 | SYK (0.43) | IDH1SYKEGFRBTKCNR2 | |
| SCHEMBL3451794 | 0.90 | SYK (0.43) | IDH1SYKEGFRBTKCNR2 | |
| SCHEMBL13311739 | 0.89 | MAPK3 (0.40) | SYKMAPK3EGFRBTKKDR | |
| SCHEMBL3448270 | 0.89 | SYK (0.37) | SYKMAPK3EGFRBTKKDR | |
| SCHEMBL3448273 | 0.89 | SYK (0.37) | SYKMAPK3EGFRBTKKDR | |
| SCHEMBL3448776 | 0.88 | THRB (0.39) | SYKMAPK3EGFRBTKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | IDH1 718/4885SYK 804/4885MAPK3 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.